Risk factors for rare diseases can be risky to define PML and natalizumab

Neurology

Volumn 81, Issue 10, 2013, Pages 858-859

  Major, Eugene O ^a   Douek, Daniel C ^b  

^a Laboratory of Molecular Medicine and Neuroscience   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

L SELECTIN; NATALIZUMAB;

BLOOD SAMPLING; CD4+ T LYMPHOCYTE; EDITORIAL; FATALITY; FREEZING; HUMAN; JC VIRUS; LONGITUDINAL STUDY; MULTIPLE SCLEROSIS; PERIPHERAL CIRCULATION; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RARE DISEASE; RISK FACTOR; THAWING;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; L-SELECTIN; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS;

EID: 84884644584     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a352a6     Document Type: Editorial

References (9)

1. Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005;8:1275.
2. Major EO. Reemergence of PML in natalizumab treated patients: new cases, same concerns. N Eng J Med 2009; 361:1041-1043.
3. Brew B, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus diseases. Nat Rev Neurol 2010;6:667-679.
4. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Eng J Med 2006;354:924-933.
5. Biogen Idec. Medical information. Available at: http://biogenidec.com/. Accessed July 31, 2013.
6. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013;81: 865-871.
7. Tan CS, Dezube BJ, Bhargave P, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV positive and HIV negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 2009;199:881-888.
8. Planas R, Jelic I, Schippling S, Martin R, Sospedra M. Natalizumab treatment perturbs memory and marginal zone like B cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 2012;42:790-798.
9. Perkins M, Ryschkewtisch CF, Liebner JC, et al. Changes in JC virus specific T cell responses during natalizumab treatment and in natalizumab associated progressive multifocal leukoencephalopathy. PLoS Pathog 2012;8:e1003014.